E Fund Management Co. Ltd. Reduces Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

E Fund Management Co. Ltd. lessened its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.2% in the fourth quarter, Holdings Channel.com reports. The firm owned 1,811 shares of the biopharmaceutical company’s stock after selling 22 shares during the period. E Fund Management Co. Ltd.’s holdings in Regeneron Pharmaceuticals were worth $1,591,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Raymond James Financial Services Advisors Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 0.5% in the third quarter. Raymond James Financial Services Advisors Inc. now owns 8,391 shares of the biopharmaceutical company’s stock worth $6,905,000 after buying an additional 42 shares in the last quarter. Stratos Wealth Partners LTD. boosted its holdings in Regeneron Pharmaceuticals by 29.4% in the 3rd quarter. Stratos Wealth Partners LTD. now owns 466 shares of the biopharmaceutical company’s stock valued at $383,000 after purchasing an additional 106 shares during the period. Brighton Jones LLC grew its position in shares of Regeneron Pharmaceuticals by 6.1% during the 3rd quarter. Brighton Jones LLC now owns 941 shares of the biopharmaceutical company’s stock valued at $774,000 after purchasing an additional 54 shares in the last quarter. WESPAC Advisors LLC bought a new position in shares of Regeneron Pharmaceuticals in the third quarter worth $276,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in shares of Regeneron Pharmaceuticals by 14.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 125,253 shares of the biopharmaceutical company’s stock worth $103,078,000 after buying an additional 15,751 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 1.3 %

Shares of REGN traded up $12.24 during mid-day trading on Thursday, hitting $968.00. 281,914 shares of the company’s stock traded hands, compared to its average volume of 493,409. The company has a quick ratio of 4.51, a current ratio of 5.27 and a debt-to-equity ratio of 0.10. The firm has a market capitalization of $106.25 billion, a P/E ratio of 28.60, a PEG ratio of 2.74 and a beta of 0.17. The business’s 50-day moving average price is $942.03 and its 200-day moving average price is $899.83. Regeneron Pharmaceuticals, Inc. has a 1 year low of $684.80 and a 1 year high of $998.33.

Analyst Ratings Changes

A number of brokerages have weighed in on REGN. BMO Capital Markets raised their price target on Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the company an “outperform” rating in a report on Monday, February 5th. Barclays lifted their target price on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the company an “overweight” rating in a research report on Tuesday, January 23rd. Royal Bank of Canada reissued an “outperform” rating and issued a $1,189.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday, April 9th. Morgan Stanley lifted their price objective on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a report on Wednesday, March 13th. Finally, TD Cowen increased their target price on Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $981.71.

Insider Activity at Regeneron Pharmaceuticals

In other news, EVP Marion Mccourt sold 358 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $967.50, for a total transaction of $346,365.00. Following the sale, the executive vice president now owns 13,431 shares of the company’s stock, valued at approximately $12,994,492.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 854 shares of the firm’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $979.25, for a total transaction of $836,279.50. Following the completion of the transaction, the director now owns 1,382 shares of the company’s stock, valued at $1,353,323.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Marion Mccourt sold 358 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $967.50, for a total transaction of $346,365.00. Following the transaction, the executive vice president now directly owns 13,431 shares of the company’s stock, valued at $12,994,492.50. The disclosure for this sale can be found here. Insiders have sold a total of 8,095 shares of company stock worth $7,779,766 over the last quarter. Corporate insiders own 8.83% of the company’s stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.